Header Logo

Connection

Shabir Madhi to Cross-Over Studies

Back to Details
This is a "connection" page, showing publications Shabir Madhi has written about Cross-Over Studies.
Shabir Madhi
Connection Strength
0,060
Cross-Over Studies
  1. Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2425147.
    View in: PubMed
    Score: 0,060
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.